Abstract
Integrating physicochemical, drug metabolism, pharmacokinetics, ADME, and toxicity assays into drug discovery in order to reduce the attrition rates in clinical development is reviewed. The review is organized around three main decision points used in discovery including hit generation, lead optimization and final candidate selection stages. The preclinical strategies used at each decision point are discussed from a drug discovery perspective. Typically, preclinical data produced at these stages use lower throughput assays, smaller amounts of compounds and operate within a timeframe that is consistent with the iterative cycle of most drug discovery research projects. Understanding the false positive rates of these drug discovery preclinical assays is a must in reducing attrition rates in development.
Current Topics in Medicinal Chemistry
Title: ADME Optimization and Toxicity Assessment in Early- and Late-Phase Drug Discovery
Volume: 9 Issue: 11
Author(s): Gary W. Caldwell, Zhengyin Yan, Weimin Tang, Malini Dasgupta and Becki Hasting
Affiliation:
Abstract: Integrating physicochemical, drug metabolism, pharmacokinetics, ADME, and toxicity assays into drug discovery in order to reduce the attrition rates in clinical development is reviewed. The review is organized around three main decision points used in discovery including hit generation, lead optimization and final candidate selection stages. The preclinical strategies used at each decision point are discussed from a drug discovery perspective. Typically, preclinical data produced at these stages use lower throughput assays, smaller amounts of compounds and operate within a timeframe that is consistent with the iterative cycle of most drug discovery research projects. Understanding the false positive rates of these drug discovery preclinical assays is a must in reducing attrition rates in development.
Export Options
About this article
Cite this article as:
Caldwell W. Gary, Yan Zhengyin, Tang Weimin, Dasgupta Malini and Hasting Becki, ADME Optimization and Toxicity Assessment in Early- and Late-Phase Drug Discovery, Current Topics in Medicinal Chemistry 2009; 9 (11) . https://dx.doi.org/10.2174/156802609789630929
DOI https://dx.doi.org/10.2174/156802609789630929 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Atypical Presentation Of Anti-Retroviral Therapy Induced Lactic Acidosis as Acute Right Ventricular Failure And Severe Pulmonary Hypertension
New Emirates Medical Journal Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Hot Topic: Targeted Therapies in the Treatment of Breast Cancer and Localized Sarcomas)
Current Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Neuroprotection by vitamin C against ethanol -induced neuroinflammation associated neurodegeneration in developing rat brain
CNS & Neurological Disorders - Drug Targets Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Proteolytic Cleavage of Notch: “HIT and RUN”
Current Molecular Medicine CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms
Current Cancer Drug Targets Naturally Occurring Hydroxytyrosol: Synthesis and Anticancer Potential
Current Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry NF-κB as a Key Mediator of Brain Inflammation in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Products in Structure-Assisted Design of Molecular Cancer Therapeutics
Current Pharmaceutical Design Overview of the Synthesis of Optically Active 3-Amino-2-Hydroxy-4-Phenylbutyric Acids, Key Intermediates for Numerous Bioactive Compounds
Mini-Reviews in Organic Chemistry Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials Reprogramming Cancer Cells in Endocrine-Related Tumors: Open Issues
Current Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology